PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors

Recruiting now · Not applicable

Conditions studied: Solid Tumor

In brief

To utilize the \[68Ga\]Ga-THP-PDL1-3 molecular probe to non-invasively detect PD-L1 expression in primary and metastatic lesions of patients with solid tumors. Furthermore, to assess the heterogeneity of PD-L1 expression within the same lesion and across different lesions, and to observe changes in PD-L1 expression during the course of treatment. This approach aims to facilitate patient screening, therapeutic monitoring, and early warning of drug resistance and/or recurrence or metastasis in the treatment of solid tumors with high PD-L1 expression, ultimately enabling personalized targeted therapy in oncology.

Key facts

Study ID

NCT06383598

Run by

Hua Zhu

People needed

50

Starts

2024-04-01

Expected to finish

2026-12-31

Last updated by the study team

2026-04-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-70 years, ECOG score 0 or 1;
• Patients with solid tumors;
• Presence of measurable lesions on imaging examinations;
• Expected survival ≥12 weeks.

You may not qualify if…

• Severe hepatic or renal dysfunction;
• Women who are planning pregnancy, pregnant, or breastfeeding;
• Unable to remain in supine position for 30 minutes;
• Refusal to participate in this clinical study;
• Diagnosis of claustrophobia or other psychiatric disorders;
• Other conditions deemed by the investigator as inappropriate for participation in the trial.

Where it is running

• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.